If you are being serious, the Ebola vaccine is pretty meaningless to their valuation right now. Anyone considering investing should only really focus on the merits of their MD drug.
I would say its a bit of coincidence on the timing. They were due to report longer term data and another company (Tekimar, sp?) got Ebola vaccine news at the same time too.
They have an ATM in place (going by memory I believe in the 40 million range).
Development stage Bio/Pharma companies always burn cash too.
I have no position in the stock.
